Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZFA02-adjuvanted quadrivalent influenza split vaccine Phase I/II trial
ChiCTR2500099285Phase 2Not yet recruiting
- Sponsor
- Hebei Provincial Center for Disease Control and Prevention
- Start
- Mar 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of influenza vaccine (split virion), inactivated, quadrivalent, ZFA02-adjuvanted in influenza (14 arms), sponsored by Hebei Provincial Center for Disease Control and Prevention. Primary endpoints: All adverse event occurrences, All adverse events of special interest occurrences and 6 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
influenza vaccine (split virion), inactivated, quadrivalent, ZFA02-adjuvanted
03
Conditions
influenza
Beyond the preview
Go deeper on ChiCTR2500099285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099285.